Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Dosulepin hydrochloride
Azure Pharmaceuticals Ltd
N06AA16
Dosulepin hydrochloride
Coated tablet
dosulepin
Not marketed
2023-04-14
Health Products Regulatory Authority 14 April 2023 CRN00CDKP Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dosulepin Hydrochloride Azure 75 mg Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 75 mg of dosulepin hydrochloride. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White circular, convex sugar-coated tablets plain on both sides. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dosulepin is indicated for the management of depression and associated anxiety. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults: _The usual total daily dose is 75 mg to 150 mg in divided doses or as a single night-time dose. Treatment should be initiated at the lower dose. In certain circumstances, _e.g. _in hospital use, dosages up to 225 mg daily have been used. Suggested regimens: 25 or 50 mg three times daily or, alternatively, 75 or 150 mg as a single dose at night. Should the regimen of 150 mg as a single night-time dose be adopted, it is better to give a smaller dose for the first few days. _Elderly: _ 50 to 75 mg daily initially. As with any antidepressant, the initial dose should be increased with caution under close supervision. Half the normal adult dose may be sufficient to produce a satisfactory clinical response. _Children: _Not recommended. Method of administration For oral administration. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Dosulepin is contraindicated following recent myocardial infarction, and in patients with any degree of heart block or other cardiac arrhythmias. It is also contraindicated in mania, severe liver disease, narrow angle glaucoma or other causes of increased intraocular pressure. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE It may be two to four weeks from the start of treatment before there is an improvement in the patient's depression; the subject should be monitored closely during this period. The anxiolytic Read the complete document